4hzl
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | ==Neutralizing antibody mAb#8 in complex with the Epitope II of HCV E2 envelope protein== | |
| - | + | <StructureSection load='4hzl' size='340' side='right' caption='[[4hzl]], [[Resolution|resolution]] 2.85Å' scene=''> | |
| - | + | == Structural highlights == | |
| + | <table><tr><td colspan='2'>[[4hzl]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus] and [http://en.wikipedia.org/wiki/Recombinant_hepatitis_c_virus_h77(5'utr-ns2)/jfh1_v787a,q1247l Recombinant hepatitis c virus h77(5'utr-ns2)/jfh1_v787a,q1247l]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4HZL OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4HZL FirstGlance]. <br> | ||
| + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4hzl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4hzl OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4hzl RCSB], [http://www.ebi.ac.uk/pdbsum/4hzl PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Hepatitis C virus (HCV) envelope glycoprotein E2 has been considered as a major target for vaccine design. Epitope II, mapped between residues 427-446 within the E2 protein, elicits antibodies that are either neutralizing or nonneutralizing. The fundamental mechanism of antibody-mediated neutralization at epitope II remains to be defined at the atomic level. Here we report the crystal structure of the epitope II peptide in complex with a monoclonal antibody (mAb#8) capable of neutralizing HCV. The complex structure revealed that this neutralizing antibody engages epitope II via interactions with both the C-terminal alpha-helix and the N-terminal loop using a bifurcated mode of action. Our structural insights into the key determinants for the antibody-mediated neutralization may contribute to the immune prophylaxis of HCV infection and the development of an effective HCV vaccine. | ||
| - | + | Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus.,Deng L, Zhong L, Struble E, Duan H, Ma L, Harman C, Yan H, Virata-Theimer ML, Zhao Z, Feinstone S, Alter H, Zhang P Proc Natl Acad Sci U S A. 2013 Apr 15. PMID:23589879<ref>PMID:23589879</ref> | |
| - | + | ||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Mus musculus]] | [[Category: Mus musculus]] | ||
| - | [[Category: Deng, L | + | [[Category: Deng, L]] |
| - | [[Category: Zhang, P | + | [[Category: Zhang, P]] |
[[Category: Ig domain]] | [[Category: Ig domain]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
[[Category: Neutralizing antibody]] | [[Category: Neutralizing antibody]] | ||
Revision as of 12:09, 21 December 2014
Neutralizing antibody mAb#8 in complex with the Epitope II of HCV E2 envelope protein
| |||||||||||
